Table 2 Prevalence of neuronal autoantibodies in the 2231 NESDA respondents.

From: Novel neuronal surface autoantibodies in plasma of patients with depression and anxiety

 

Current depression or anxiety (N = 819)a

Depression or anxiety in remission (N = 920)b

Control group (N = 492)

P value

IHC score 1, 2, or 3c

44 (5.4%)

37 (4.0%)

25 (5.1%)

N/Sd

 Borderline (Score 1)

23 (2.8%)

19 (2.1%)

14 (2.8%)

N/S

 Weak positive (Score 2)

15 (1.8%)

16 (1.7%)

11 (2.2%)

N/S

 Strong positive (Score 3)

6 (0.7%)

2 (0.2%)

0

N/S (0.071)

Positive by IHC and staining on live neurons (Novel NSAbs)e

7 (0.9%)

0

1 (0.2%)

0.006

Positive by IHC and fixed CBAf

1 (0.1%)

1 (0.1%)

0

 

 Anti-CASPR2

0

1 (0.1%)

0

N/S

 Anti-GAD65/67

1 (0.1%)

0

0

N/S

 Othersg

0

0

0

N/S

Positive by IHC and live CBAf

3 (0.4%)

8 (0.9%)

2 (0.4%)

 

 Anti-NMDAR/Anti-AMPAR

0

0

0

N/S

 Anti-CASPR2

1 (0.1%)

5 (0.5%)

2 (0.4%)

N/S

 Anti-LGI1

0

1 (0.1%)

0

N/S

 Anti-GABAAR

0

1 (0.1%)

0

N/S

 Anti-GABABR

2 (0.2%)

1 (0.1%)

0

N/S

  1. aDepression and/or anxiety present in the 6 months prior to assessment.
  2. bLifetime depression and/or anxiety diagnosis, but not in the 5 months prior to assessment.
  3. cIn all, 2231 were tested by IHC.
  4. dN/S: no significant difference. α = 0.05
  5. e,fSamples with IHC score 1, 2, or 3 (N = 106) were further tested by staining on live neurons and CBA.
  6. gAnti-NMDAR, anti-AMPAR, anti-LGI1, anti-GABAAR, and anti-GABABR.
Back to article page